Risperidone versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Rattehalli, Ranganath D ^a   Jayaram, M B ^b  

^a Millfield House   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; PUBLISHING; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; META ANALYSIS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; HUMANS; PLACEBOS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 44949236138     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006918     Document Type: Review

References (24)

1. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996 Nov 9;313(7066):1200.
2. Benson 1996 Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it "remembered wellness". Annual review of medicine 1996;47:193-9. [MEDLINE: 8712773].
3. Bland 1997 Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
4. Carpenter 1994 Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl JMed 1994 Mar 10;330(10):681-90. [MEDLINE: 8107719].
5. Carpenter 2003 Carpenter WT Jr, Appelbaum PS, Levine RJ. The Declaration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. American Journal of Psychiatry 2003;160(2):356-62.
6. Darby 1997 Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1997 Dec; 17(6):478-84. [MEDLINE: 9408811].
7. Divine 1992 Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. J Gen Intern Med 1992 Nov-Dec;7(6):623-9.
8. Donner 2002 Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
9. Egger 1997 Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
10. Gilbody 2000 Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 3.Art. No.: CD002306. DOI:10.1002/14651858.CD002306.
11. Gulliford 1999 Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
12. Heykants 1994 Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry 1994;55 Suppl(May):13-7. [MEDLINE: 7520903].
13. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Cochrane Database of Systematic Reviews 2005, Issue 3.
15. Hosalli 2003 Hosalli P, Davis JM. Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4.Art. No.: CD004161. DOI:10.1002/14651858.CD004161.
16. Hunter 2003 Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD000440. DOI:10.1002/14651858.CD000440.
17. Jayaram 2006 Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2.Art. No.: CD005237. DOI:10.1002/14651858.CD005237.pub2.
18. Joy 2006 Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4.Art. No.: CD003082. DOI:10.1002/14651858.CD003082.pub2..
19. Komossa 2007 Komossa K, Rummel C, Hunger H, Schmidt F, Schwarz S, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia (protocol). Cochrane Database of Systematic Reviews 2007, Issue 3.
20. Laughren 2001 Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry 2001;16(7):418-23.
21. Leysen 1994 Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry 1994;55 Suppl(May):5-12. [MEDLINE: 7520908].
22. Marshall 2000 Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000 Mar;176:249-52. [MEDLINE: 10755072].
23. Ukoumunne 1999 Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
24. Vallance 2006 Vallance AK. Something out of nothing: the placebo effect. Advances in Psychiatric Treatment 2006;12:287-96.